SCHEMBL4841405

SCHEMBL4841405

OC1COCC1Nc1nc(Oc2ccc(F)cc2F)nc2[nH]nc(-c3ccccc3Cl)c12

nearest known ligand 0.41

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 15/20 0.41
TYRO3 Q06418 2/20 0.37
DGAT2 Q96PD7 1/20 0.33
SELP P16109 1/20 0.33
MAPK11 Q15759 1/20 0.32
TRPA1 O75762 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14018947 1.00 MAPK14 (0.41) MAPK14TYRO3DGAT2SELPMAPK11
SCHEMBL14018929 0.93 MAPK14 (0.45) MAPK14DGAT2
SCHEMBL4844405 0.93 MAPK14 (0.45) MAPK14DGAT2
SCHEMBL4832823 0.88 MAPK14 (0.40) MAPK14DGAT2
SCHEMBL14018856 0.88 MAPK14 (0.40) MAPK14DGAT2
SCHEMBL14018863 0.88 MAPK14 (0.40) MAPK14DGAT2
SCHEMBL4842964 0.88 MAPK14 (0.40) MAPK14DGAT2
SCHEMBL14018903 0.84 MAPK14 (0.41) MAPK14MAPK11
SCHEMBL4842899 0.84 MAPK14 (0.41) MAPK14MAPK11
SCHEMBL4839439 0.82 MAPK14 (0.46) MAPK14MAPK11TRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7435731-B2 Substituted pyrazolo[3,4-d]pyrimadines and methods of using the same ROCHE PALO ALTO LLC (US) 2008-10-14 US claimed
US-7435731-B2 Substituted pyrazolo[3,4-d]pyrimadines and methods of using the same ROCHE PALO ALTO LLC (US) 2008-10-14 US disclosed
US-20050197340-A1 Fused-pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives and methods for using the same ROCHE PALO ALTO LLC 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197340-A1 Fused-pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives and methods for using the same MAP3K1, MAPK1, MAP3K8 MAPK14 70/4885TYRO3 442/4885DGAT2 4662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.